Military Training Exercises, Pollution, and their Consequences for Health

from Health Economics at http://bit.ly/2P6NgKI on August 19, 2019 at 05:50PM Militaries around the world perform training exercises in preparation for war. We study the relationship between in utero exposure to military exercises (bombing) and early-life health outcomes, combining data on naval bombing exercises in Vieques, Puerto Rico, and the universe of births from 1990-2003. […]

Long-run consequences of informal elderly care and implications of public long-term care insurance

from Health Economics at http://bit.ly/2z61jpf on August 19, 2019 at 05:50PM In this paper, I estimate a dynamic structural model of labor supply, retirement, and informal care supply, incorporating labor market frictions and the German tax and benefit system. I find that informal elderly care has adverse and persistent effects on labor market outcomes and […]

Mental Health around Pregnancy and Child Development from Early Childhood to Adolescence

from Health Economics at http://bit.ly/2P4xRdV on August 19, 2019 at 05:50PM We identify the causal effect of mothers’ mental health during early – and soon after pregnancy on a range of child psychological, socio-emotional and cognitive outcomes measured between ages 4-16. Results suggest a negative effect on children’s psychological and socio-emotional skills in early childhood, […]

Measuring the activity of mental health services in England: variation in categorising activity for payment purposes

from Health Economics at http://bit.ly/2zaALTO on August 19, 2019 at 05:50PM In the context of international interest in reforming mental health payment systems, national policy in England has sought to move towards an episodic funding approach. Patients are categorised into care clusters, and providers will be paid for episodes of care for patients within each […]

Patents, Data Exclusivity, and the Development of New Drugs

from Health Economics at http://bit.ly/33qQRXa on August 12, 2019 at 02:46PM Pharmaceutical firms typically enjoy market exclusivity for new drugs from concurrent protection of the underlying invention (through patents) and the clinical trials data submitted for market approval (through data exclusivity). Patent invalidation during drug development renders data exclusivity the sole source of protection and […]